|
|
Volumn 2012, Issue , 2012, Pages 49-55
|
|
Myelodysplastic syndromes: who and when in the course of disease to transplant.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CANCER VACCINE;
DNA METHYLTRANSFERASE;
ADULT;
AGE;
AGED;
CLINICAL TRIAL (TOPIC);
COMORBIDITY;
CYTOLOGY;
DISEASE FREE SURVIVAL;
DNA METHYLATION;
DRUG ANTAGONISM;
HUMAN;
IMMUNOTHERAPY;
LYMPHOCYTE;
METHODOLOGY;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROME;
ONCOLOGY;
QUALITY OF LIFE;
RECURRENT DISEASE;
REGISTER;
REVIEW;
RISK;
SIBLING;
STEM CELL TRANSPLANTATION;
TREATMENT OUTCOME;
ADULT;
AGE FACTORS;
AGED;
ANTINEOPLASTIC AGENTS;
CANCER VACCINES;
CLINICAL TRIALS AS TOPIC;
COMORBIDITY;
DISEASE-FREE SURVIVAL;
DNA METHYLATION;
DNA MODIFICATION METHYLASES;
HUMANS;
IMMUNOTHERAPY;
LYMPHOCYTES;
MEDICAL ONCOLOGY;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
QUALITY OF LIFE;
RECURRENCE;
REGISTRIES;
RISK;
SIBLINGS;
STEM CELL TRANSPLANTATION;
TREATMENT OUTCOME;
|
|
EID: 84878308993
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation.v2012.1.49.3798189 Document Type: Review |
|
Times cited : (16)
|
|
References (0)
|
